You should consider shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) and American Tower Corporation (REIT) (NYSE:AMT) if you are looking for a great stocks to invest in. Starting with the SUPN shares, which traded at $23.04 at the close of the recent session, gaining 1.59%. On Tuesday, the company’s shares shed $0.36 from its value which represented in intraday trading. The stock is now -51.41% lower in year-to-date (YTD) trading. SUPN’s intraday high was $23.26 while its lowest price touched $22.35. The stock’s 52-week high price is $49.25, which means the current price is at -53.22%. In terms of trading activity, the daily trading volume rose to 1552724 against 200-day average trading volume of 588,669 shares.
What are analyst forecasts for Supernus Pharmaceuticals Inc. (NASDAQ:SUPN)?
At a consensus rating of 3.67, SUPN is trending as a streaking Moderate Buy, as it has been the case a month ago when 5 analysts called it a Strong Buy. Two months ago, 5 analysts recommended, on average, that SUPN stock is a Strong Buy. The Healthcare company’s shares’ overall bullish trend saw it close higher on Tuesday compared to its opening price of $22.35 on the day.
Forecasts for Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) give the stock a fair value for the growth of 1.96% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $23.50, which means the price per share could rise by nearly $0.46. The price range target is between a low of $22.00 and a high of $32.00. The stock would need to gain by about $28.0 to hit the estimated high or 0.84% from its 12-month low.
The consensus among 6 analysts is that it is a good time for one to Overweight in the Supernus Pharmaceuticals Inc. 2 analysts rate SUPN as a Buy, with 0 of 6 analysts rate it as a Sell. 0 have valued the stock as Overweight and 4 have recommended that investors Hold.
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) Upgrades and Downgrades
In terms of rating changes, Berenberg on November 08, 2019, Downgrade Supernus Pharmaceuticals Inc. (SUPN) at Hold. Analysts at Stifel have assigned a Hold rating for the stock in their research note on November 07, 2019 with an estimated price target of $23. Moreover, Jefferies analysts issued a rating of Hold for the stock on November 06, 2019, giving it a price target of $23 for the next 12 months. On November 12, 2018, the stock earned a Buy rating due to an analyst call from B. Riley FBR, while analysts from B. Riley FBR Inc. on January 18, 2018 suggested that the stock is Buy.
American Tower Corporation (REIT) (NYSE:AMT) adds $1.64 on Tuesday
The AMT stock has risen 33.52% year-to-date and is currently trading at $211.21, which is -12.72% below its 52-week high. The company shares gained 0.78% on the day and have risen nearly 40.19% off a low hit. At current levels, American Tower Corporation (REIT) has a valuation of about $7.79B. As of 12/03/19, this stock has risen 0.72% during the week and closed at $209.57 in the previous session. However, recent American Tower Corporation (REIT) stock performance shows that AMT shares are -2.00% down over the last month, and -12.39% down for the last three months.
Earnings per share (EPS) estimates for the current quarter are $0.77, with the trailing 12-month share earnings at $3.60. The ratio is expected to be up by 44.80% for the current year 2019 and 13.20% for next year. Over the next 5-year period, earnings per share will be 22.80%. But will the AMT stock surprise in the current quarter results, where the $1.12 actual EPS reported on 9/29/2019 surprised by 17.90% or was higher by $0.17 from the estimated $0.95.
Sales Growth to climb 6.30% for the year
How well will American Tower Corporation (REIT) perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $1.88B and $1.96B in current quarter sales. The consensus estimated for the current quarter is $1.93B from sales. Forecasts for this fiscal year are between $7.57B and $7.62B and the consensus estimate for sales is at $7.59B. AMT has its next quarter sales estimates at between $1.96B and $2.03B, with the quarter-over-quarter growth estimates at 10.10% and the annual growth forecast for the year at 6.30%.
Who owns shares in American Tower Corporation (REIT) (AMT)?
Let’s briefly focus on the share ownership of the American Tower Corporation (REIT) (NYSE:AMT) stock, where we find that 95.72% of shares are held by institutions. Vanguard Group, Inc. (The) tops the list of institutional owners as it is holding 58.01 million shares or 13.10% of shares outstanding. Blackrock Inc. and FMR, LLC held 32.45 million and 19.36 million representing 7.33% and 4.37% respectively at the close of the last trading session. As of Sep 29, 2019, State Street Corporation accounted for 18.61 million shares at over 4.12 billion. This represented 4.20% of shares outstanding. Wellington Management Company, LLP held 18.3 million shares at over 4.05 billion representing 4.13% of shares outstanding.
AMT Insider Activity
Insider activity can also give a signal in terms of price direction. Looking at American Tower Corporation (REIT) (AMT), a total of 332694 shares have been sold by insiders over the last 6 months while 300768 shares were added in the same time span. On 1/18/2019, Chief Financial Officer & Executive Vice President by the name Bartlett Thomas A sold 51203.0 shares worth $8.4 million at the price of $165.00 per share. Filings also show that Disanto Edmund sold a total of 34949.0 shares on 10/04/2019 valued at $7.9 million. Since the last insider activity, the company’s share price has dropped -7.24%.